source
- Novartis to cut about 130 jobs in Switzerland as it reshapes biologics production in BaselNovartis announced it will eliminate roughly 130 positions in Switzerland as part of a reorganization of its biologics technical development and manufacturing footprint in Basel. The company plans…
- Teva's anti-IL-15 antibody meets primary endpoint in phase 2a celiac disease trialTeva Pharmaceuticals reported that its anti‑interleukin‑15 antibody, TEV‑408, achieved the primary endpoint in a phase 2a study of 50 adults with celiac disease. Participants received a single dose…